title: Two enhancers control transcription of Drosophila muscleblind in the embryonic somatic musculature and in the central nervous system.
abstract: The phylogenetically conserved family of Muscleblind proteins are RNA-binding factors involved in a variety of gene expression processes including alternative splicing regulation, RNA stability and subcellular localization, and miRNA biogenesis, which typically contribute to cell-type specific differentiation. In humans, sequestration of Muscleblind-like proteins MBNL1 and MBNL2 has been implicated in degenerative disorders, particularly expansion diseases such as myotonic dystrophy type 1 and 2. Drosophila muscleblind was previously shown to be expressed in embryonic somatic and visceral muscle subtypes, and in the central nervous system, and to depend on Mef2 for transcriptional activation. Genomic approaches have pointed out candidate gene promoters and tissue-specific enhancers, but experimental confirmation of their regulatory roles was lacking. In our study, luciferase reporter assays in S2 cells confirmed that regions P1 (515 bp) and P2 (573 bp), involving the beginning of exon 1 and exon 2, respectively, were able to initiate RNA transcription. Similarly, transgenic Drosophila embryos carrying enhancer reporter constructs supported the existence of two regulatory regions which control embryonic expression of muscleblind in the central nerve cord (NE, neural enhancer; 830 bp) and somatic (skeletal) musculature (ME, muscle enhancer; 3.3 kb). Both NE and ME were able to boost expression from the Hsp70 heterologous promoter. In S2 cell assays most of the ME enhancer activation could be further narrowed down to a 1200 bp subregion (ME.3), which contains predicted binding sites for the Mef2 transcription factor. The present study constitutes the first characterization of muscleblind enhancers and will contribute to a deeper understanding of the transcriptional regulation of the gene.
authors.affiliation: Translational Genomics Group, Department of Genetics, University of Valencia, Valencia, Spain; INCLIVA Health Research Institute, Valencia, Spain.
authors.forename: Ariadna
authors.initials: A
authors.lastname: Bargiela
authors.affiliation: Translational Genomics Group, Department of Genetics, University of Valencia, Valencia, Spain; INCLIVA Health Research Institute, Valencia, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Llamusi
authors.affiliation: Translational Genomics Group, Department of Genetics, University of Valencia, Valencia, Spain; INCLIVA Health Research Institute, Valencia, Spain.
authors.forename: Estefanía
authors.initials: E
authors.lastname: Cerro-Herreros
authors.affiliation: Translational Genomics Group, Department of Genetics, University of Valencia, Valencia, Spain; INCLIVA Health Research Institute, Valencia, Spain.
authors.forename: Ruben
authors.initials: R
authors.lastname: Artero
mesh_terms: D000818:Animals; D001483:Base Sequence; D002490:Central Nervous System / Q000196:embryology* / Q000378:metabolism; D017124:Conserved Sequence; D004330:Drosophila / Q000196:embryology* / Q000235:genetics*; D004742:Enhancer Elements, Genetic / Q000235:genetics; D018507:Gene Expression Regulation, Developmental; D017930:Genes, Reporter / Q000235:genetics; D023281:Genomics; D006801:Humans; D008969:Molecular Sequence Data; D009132:Muscles / Q000196:embryology* / Q000378:metabolism; D009928:Organ Specificity; D011401:Promoter Regions, Genetic / Q000235:genetics; D016601:RNA-Binding Proteins / Q000235:genetics; D014158:Transcription, Genetic
chemical_list: C493663:MBNL1 protein, human; D016601:RNA-Binding Proteins